Teicoplanin
Alternative Names: MDL 507; Targocid; TeichomycinLatest Information Update: 05 Nov 2023
At a glance
- Originator Pfizer
- Class Antibacterials; Glycopeptides; Peptide antibiotics
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Bacterial infections; Gram-positive infections
Most Recent Events
- 01 Jul 2019 Sanofi plans a phase IV trial in Gram-positive infections (Clostridium difficile infections) (NCT04003818)
- 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma